Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. UC Irvine scientists discover possible baldness cure.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

Minoxidil was applied to a single miniaturized hair follicle over four months, resulting in less miniaturization but not yet terminal growth. The user used a 5% minoxidil solution, specifically the Regaine brand, and observed changes using a handheld WiFi microscope.

A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.

Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.

A trans man shared his 5-month progress using finasteride and minoxidil for temple regrowth, noting slow but steady results. Despite some negative comments, he received support and encouragement from others, with advice to start treatment early for best results.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A 22-year-old male is using Dutasteride, Minoxidil, RU58841, and Microneedling to treat hair loss and is wondering if he can regrow hair at his temples. Commenters suggest that he should continue the treatment as it takes time, with full results expected in 2-2.5 years.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

Tretinoin and microneedling both enhance hair growth through different mechanisms, with microneedling being considered safe for long-term use. Optimal microneedling needle length varies, but 0.8 mm is suggested for hair growth, and a Dermastamp is recommended to avoid skin damage.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The conversation is about whether treatments like finasteride, dutasteride, and minoxidil can make single hair follicles produce multiple hairs again. The user is curious if these medications can thicken hair and prolong the growth phase.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

Tadalafil combined with finasteride seems to improve hair condition for the original poster, who has experienced gradual improvement in hair thinning. Other users discuss the effects of tadalafil on blood flow and its potential benefits for hair growth.

A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.

A 22-year-old male shares his 2-month progress using a regimen of 0.5mg dutasteride daily, 1.5mm dermarolling weekly, a daily multivitamin, and a topical serum with 10% minoxidil and 0.1% finasteride. He reports impressive hair regrowth, especially at the hairline, and has experienced no sexual side effects.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

Exploring the idea of transplanting miniaturized hair follicles to healthier areas to potentially reverse hair loss, with concerns about DHT sensitivity and scar tissue formation. The conversation also humorously considers using mice for hair growth experiments.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.